Skip to content

Chicago Jury Finds AbbVie Fraudulently Marketed AndroGel to Injured Oregon Man; Awards $150 Million in Punitive Damages

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug. “This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. […]

July 24, 2017

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug.

“This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears it,” said MDL co-lead counsel Chris Seeger.  Mr. Mitchell is one of more than 4,000 plaintiffs who have sued AbbVie Inc. in the federal multidistrict litigation, In re: Testosterone Replacement Therapy Products Liability Litigation, case number 1:14-cv-01748, before Judge Matthew Kennelly in the U.S. District Court for the Northern District of Illinois. Mr. Mitchell claimed that AbbVie fraudulently misled doctors and patients about the drug’s benefits and risks—in particular, cardiovascular risks—when marketing the drug. The jury deliberated for 4 hours before reaching its verdict.  Partner Dave Buchanan, a member of the Mitchell trial team, commented, “For years before Jesse took AndroGel, AbbVie promoted unproven benefits and falsely assured doctors and patients about the safety of the drug.  The consequences of those acts are serious and real—facts that weren’t lost on this jury.”

Mr. Mitchell was represented by Troy Rafferty of Levin Papantonio, lead, David Buchanan of Seeger WeissBill Robins of Robins Cloud, Stephanie O’Connor of Douglas & London, and David Diamond of Goldberg & Osborne. The case is Mitchell et al. v. AbbVie Inc. et al., case number 1:14-cv-09178.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.

Related News

December 1, 2022
Seeger Weiss now accepting applicants for 2023 Diversity Fellowship

Seeger Weiss LLP announced today that the application period for the firm’s 2023 Diversity Fellowship is now open. Seeger Weiss is committed to providing an inclusive, equitable workplace where team members from all backgrounds can thrive and grow. We believe that diversity makes workplaces, institutions, and our world stronger, smarter, more resilient, and more just. […]

Read More
November 11, 2022
Chris Seeger appointed co-lead counsel in In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation

Seeger Weiss is proud to announce founder Chris Seeger has been appointed to serve as co-lead counsel in the In Re: Social Media Adolescent Addiction/Personal Injury Products Liability Litigation by the honorable Judge Yvonne Gonzalez Rogers. Seeger was one of three lawyers selected to lead the multidistrict litigation pending in the Northern District of California, […]

Read More
November 4, 2022
Seeger Weiss founding partner Chris Seeger helps negotiate $10 billion agreements with Walgreens and CVS in National Prescription Opiate Litigation

Seeger Weiss founding partner Chris Seeger along with partner Jennifer Scullion helped lead the National Prescription Opiate Litigation team in negotiations with Walgreens and CVS that culminated in over $10 billion in settlement agreements to help communities across the country ravaged by the opioid epidemic. In addition to Seeger and Scullion, negotiations were led by […]

Read More